<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01500343</url>
  </required_header>
  <id_info>
    <org_study_id>UFF-Cardiologia-01</org_study_id>
    <nct_id>NCT01500343</nct_id>
  </id_info>
  <brief_title>A Pilot Study of Probiotic Saccharomyces Boulardii Use in Chronic Heart Failure Patients. Estudo PROICA</brief_title>
  <acronym>PROICA</acronym>
  <official_title>A Pilot Study of Probiotic Saccharomyces Boulardii Use in Chronic Heart Failure Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Federal Fluminense</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidade Federal Fluminense</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the feasibility, safety and effects in inflammatory
      response of the therapy with a probiotic agent, the yeast Saccharomyces boulardii (SB), in
      chronic heart failure patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A cardiointestinal syndrome has been described in heart failure patients, with morphologic
      and functional intestinal disorders, increased enteropathogenic bacteria concentration,
      bacterial translocation and inflammatory activation, thus contributing for clinical worsening
      and progression of the disease.

      In clinical practice, probiotics has been used in several different conditions, as
      inflammatory bowel diseases, acute and antibiotic-associated diarrhea, food allergies, and
      cancer, showing benefits in inflammation and reducing bacterial translocation. However, the
      use of probiotics in heart failure has never been described.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Analysis of biochemical profile (high-sensitivity C reactive protein, total leukocyte count and uric acid seric levels)</measure>
    <time_frame>3 months</time_frame>
    <description>Analysis at baseline and after intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analysis of cardiac remodelling</measure>
    <time_frame>3 months</time_frame>
    <description>Ecocardiographic analysis of left atrial diameter and left ventricular ejection fraction at baseline and after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of creatinine seric levels</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Saccharomyces boulardii</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saccharomyces boulardii</intervention_name>
    <description>1 gram per day, during 3 months</description>
    <arm_group_label>Saccharomyces boulardii</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Class I or II (NYHA)heart failure patients

        Exclusion Criteria:

          -  Corticosteroid use within 30 days

          -  NSAID use within 30 days

          -  Antibiotic use within 30 days

          -  Acute infections

          -  Inflammatory diseases

          -  Autoimmune diseases

          -  Cancer

          -  Intestinal diseases

          -  Chronic renal failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annelise C Costanza, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidade Federal Fluminense</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Evandro T Mesquita, MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>Universidade Federal Fluminense</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universit√°rio Antonio Pedro</name>
      <address>
        <city>Niteroi</city>
        <state>Rio de Janeiro</state>
        <zip>24033-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2011</study_first_submitted>
  <study_first_submitted_qc>December 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2011</study_first_posted>
  <last_update_submitted>December 27, 2011</last_update_submitted>
  <last_update_submitted_qc>December 27, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 28, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidade Federal Fluminense</investigator_affiliation>
    <investigator_full_name>Annelise Cisari Costanza</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>heart failure</keyword>
  <keyword>probiotics</keyword>
  <keyword>Saccharomyces boulardii</keyword>
  <keyword>cardio-intestinal syndrome</keyword>
  <keyword>gut</keyword>
  <keyword>inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

